Pancreatin-responsive bioactive peptide, nanofiber hydrogel prepared from pancreatin-responsive bioactive peptide and application of pancreatin-responsive bioactive peptide
By designing the bioactive peptide 1-Pept that responds to tryptic enzymes and doxorubicin co-assembled with doxorubicin to form a nanofiber hydrogel, the problem of unselective distribution of doxorubicin in vivo and limited response rate is solved, and efficient treatment of colorectal cancer is achieved and toxic side effects are reduced.
CN119751562AActive Publication Date: 2025-04-04HENAN UNIV OF CHINESE MEDICINE
4 Cites 1 Cited by
Patent Information
- Application Number
- CN202411757004.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-12-03
- Publication Date
- 2025-04-04
- Estimated Expiration
- 2044-12-03
AI Technical Summary
Technical Problem
The existing anti-colon cancer drug doxorubicin is not selective in the body, the response rate is limited and accompanied by toxic side effects, making it difficult to effectively treat colorectal cancer.
Method used
By designing a trypsin-responsive bioactive peptide 1-Pept and co-assembly with doxorubicin to form nanofiber hydrogel 1-Pept/Dox NFs, the nanofiber hydrogel can be transformed into a dense structure in the presence of trypsin, enhancing the intracellular uptake of drugs and anti-cancer effects.
Benefits of technology
The selective retention of doxorubicin in the colon cancer site and enhance intracellular uptake is achieved, which significantly improves the anti-colon cancer effect and reduces the toxic side effects of the drug.
✦ Generated by Eureka AI based on patent content.
Abstract
The invention belongs to the technical field of cancer drugs, and particularly relates to a pancreatin-responsive bioactive peptide, nanofiber hydrogel prepared from the pancreatin-responsive bioactive peptide and application of the pancreatin-responsive bioactive peptide. The trypsin response-based bioactive peptide 1-Pept (the sequence of the trypsin response-based bioactive peptide 1-Pept is naphthylacetic acid-phenylalanine-glycine-tyrosine-lysine-cysteine-aspartic acid) and an anti-cancer drug adriamycin can be jointly assembled into 1-Pept / Dox nanofiber hydrogel, and a cytoskeleton can be destroyed by combining nanofibers with Dox; a series of cascade events resulting in cellular dysfunction are initiated, including mitochondrial damage, activation of apoptosis-associated proteins, and nuclear damage, thereby cooperatively causing tumor ablation. Compared with the existing single anti-cancer drug adriamycin, the in-vivo and in-vitro anti-cancer effect of the compound is obviously superior to that of the adriamycin pure drug, and the compound has obvious advantages in the aspect of resisting colon cancer.
Need to check novelty before this filing date? Find Prior Art